Specialized pharma venture dedicated to tackling anti-microbial resistance through innovation, stewardship and access.

Breakthrough technology combining immune system decryption with actionable predictive information to optimize preventive strategies, and develop new treatments or medical devices.First use case : assessment of postoperative complications risk for gastro-intestinal surgery patients, allowing for the adaptation of preoperative, operative and postoperative protocols.

Synthetic-biology biotech developing point-of-care molecular diagnostic technology towards any DNA or RNA pathogen. Starting first with Lyme disease.

Comprehensive AI-based solution to manage hospital medical pictures – from medical imaging library to patient remote monitoring. Already active as a chronic wound management solution.

The first all-in-one ambient AI health hub. Revolutionizing healthcare delivery in senior living facilities, through contactless vital sign monitoring and comprehensive mobility assessments.

Leading Ipsen CHC team in the first steps of its integration with the new owner Mayoly (after having led its turn-around, carve-out and divestment).

Challenge: establish an autonomous CHC business & create a sustainable future for it Span: - Fully fledged Business Unit of 1250 people / 275m€ revenues- Commercial operations in >80 countries. Direct presence in 15 affiliates, incl. China, Russia, Europe and Algeria- 3 manufacturing sites in France & ChinaAchievements- Business model transformation from Primary Care into Consumer Healthcare - Adaptation to generic pressure and Covid-19 major impact - Portfolio revitalization (incl. Smecta brand) ; footprint expansion - Manufacturing sites revamping and sharp decrease in GHG emissions- Successful carve out & divestment to Mayoly, leading to the creation of a promising new CHC champion

Challenge : adapt Asia Pacific commercial footprint to the Group's new ambition in oncologySpan:- 300 people / 150m€ sales- Direct presence in China, Korea, Taiwan and Australia ; partnerships with liaison teams in Japan and Singapore- Therapeutic areas : oncology, endocrinology and neurologyAchievements: - Commercial model revamping in China- Full turnaround of the affiliate in Korea, from loss-making to a high growth and profitable- Creation of a hub in Singapore to develop South Asia business- Transition from distributor to direct presence in Taiwan- Launch of two oncology products in selected geographies : Somatuline in Neuro-Endocrine Tumors ; Cabometyx in Renal Cell Carcinoma

Challenge : Lead Ipsen #1 country in the dual move of maximizing Specialty care growth and protecting Primary Care profitability at a time of massive sales dropSpan:430 people / ~250m€ sales in 2012.Portfolio : Specialty Care hospital drugs (oncology, endocrinology and neurology) and Primary Care prescription drugs (cardiology, rheumatology and GI)Achievements: - Major restructuring (-170 positions) successfully operated in 9 months, with limited disruption and while reaching budget targets- Specialty care growth maximized (+5%) without any new launch- Adaptation to regular price cuts and product delisting

Management of the marketing and sales teams. Portfolio : cardiology, rheumatology and GI280 people / 175m€ revenues in 2010 Achievement : - Successful launch of Adenuric (first major innovation in gout for the last 40 years)- Defense of the regulatory status for mature products- Sales force restructuring in the context of a sharp drop in revenuesAdditional assignement : Corporate Leader for Primary Care life cycle management projects.Coordination of a multi-disciplinary team of 12 people : research, clinical and pharmaceutical development, regulatory, manufacturing, marketing, medical and business development.

Coordination of the annual construction of the Group’s strategic planAdhoc projects for the Executive Committee : BD target screening ; asset divestment ; organization design

Strategic analysis and operational effectiveness assignements.Mostly for retail, industry and energy players.